We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018

By Theresa Herman, Regional Director
Posted on 27 Mar 2019
Print article
Image: The CL900i benchtop analyzer (Photo courtesy of Mindray Medical).
Image: The CL900i benchtop analyzer (Photo courtesy of Mindray Medical).
Mindray Medical (Shenzhen, China), a leading provider of IVD devices and reagents with core business in hematology, clinical chemistry and CLIA, showcased one of the world's smallest, fully automated chemiluminescence immunoassay analyzers at AACC, the world’s largest exposition for clinical laboratory products and services. This year’s annual event was held in Chicago, Illinois, USA, from July 31 to August 2.

Mindray’s solutions cover diverse laboratory needs worldwide. The company offers industry leading hematology analyzers and scalable automation lines, wide-range chemistry analyzers with traceable reagents, immunoassay systems with full assays, and products in flow cytometry, HPLC analysis, coagulation, etc.

At AACC, Mindray also unveiled the CL900i – a fully automated benchtop chemiluminescence immunoassay system with industry-leading small size that helps maximize laboratory space. With its industry-leading small footprint, fast throughput of 180 tests per hour and zero user maintenance, the CL900i benchtop analyzer provides easy and quality CLIA testing without taking up valuable laboratory floor space. The CL900i offers a broad range of testing results, 50 positions for reagents and 50 positions for samples, making it ideal for small laboratories looking for savings in cost as well as space and having high standards of quality.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.